Before relying on a price Prices, delivery fees, stock and eligibility checks can change. Confirm current details directly with the provider before relying on a comparison.
Independent UK guide to Mounjaro eligibility, BMI thresholds, medical suitability, cautions, and the difference between NHS access and private-provider pathways.
BMI 27+
May be considered by some private providers where there is a relevant weight-related condition
BMI 30+
Common starting point for many private-provider assessments
BMI 35+
Core NICE threshold for NHS obesity guidance, with at least 1 weight-related comorbidity
Mounjaro is a prescription-only treatment. That means access depends on clinical suitability and prescriber review, not just whether you want to order it. BMI is one of the starting points, but providers also look at your wider medical history, current medication, contraindications, and whether treatment appears appropriate overall.
Quick overview: many private providers commonly assess adults with obesity, and some may also consider people with a lower BMI where there is a relevant weight-related condition. NHS access is narrower and follows NICE guidance rather than standard private-provider screening.
BMI thresholds in practice
BMI is widely used in UK obesity assessment, but it is not the only factor. Providers should still consider the broader clinical picture.
Common private-provider starting point
BMI 30 or above: often a typical starting point for private-provider assessment.
Not automatic approval: a provider may still decline if treatment does not look suitable after review.
Lower BMI with a relevant health condition
BMI 27 or above: some private providers may consider treatment where there is a relevant weight-related condition.
Examples commonly reviewed include:
Type 2 diabetes or prediabetes
High blood pressure
High cholesterol or dyslipidaemia
Obstructive sleep apnoea
Cardiovascular risk factors or established cardiovascular disease
PCOS
Non-alcoholic fatty liver disease
Below BMI 27
Routine prescribing is usually less likely.
Providers would usually want stronger clinical justification than a general weight-loss preference alone.
Quick reference
Adults only
Providers generally assess adults aged 18 and over.
Full review
Suitability depends on more than BMI alone.
Ethnicity thresholds
Lower BMI thresholds are often relevant for some ethnic backgrounds.
NHS vs private
NHS access is narrower than most private-provider pathways.
Useful check: BMI remains a screening tool, but it has limitations and does not replace full clinical assessment.
General medical suitability
Age
Adults only: treatment is generally assessed in adults aged 18 and over.
Older adults: there is no simple upper age cut-off, but review may be more cautious where there are multiple medical conditions, frailty concerns, or polypharmacy.
Previous weight-management efforts
NHS pathways usually place more emphasis on structured weight-management history and service criteria.
Private providers also commonly review lifestyle context, goals, and whether treatment is being used as part of a broader plan.
Mental health and eating-disorder considerations
Active eating disorders: these usually need careful review and may make prescribing inappropriate.
Binge eating disorder: often reviewed case by case rather than assumed either way.
Depression, anxiety, or body-image concerns: these do not automatically prevent treatment, but they may affect how suitability is assessed.
What providers usually assess
Current medication and possible interactions
Past medical conditions, including pancreatic, thyroid, kidney, or gallbladder issues
Relevant family history where appropriate
Medication allergies or previous reactions
Mental-health and eating-disorder history where relevant
Weight and height for BMI review
Blood pressure or recent clinical information where needed
Previous weight-management approaches and treatment goals
Understanding of side effects, follow-up, and realistic expectations
Situations where Mounjaro may not be appropriate
Usually treated as strong reasons not to use tirzepatide
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Known hypersensitivity to tirzepatide or an ingredient in the product
Pregnancy
Breastfeeding may also require avoiding treatment or stopping breastfeeding, depending on clinical advice
Situations that often need closer review
History of pancreatitis
Severe gastroparesis or significant digestive motility problems
Gallbladder disease
Kidney impairment, especially where dehydration risk is relevant
Use with insulin or sulphonylureas, where hypoglycaemia precautions may matter
Pregnancy, fertility, and contraception
Pregnancy
Mounjaro should not be used during pregnancy.
If pregnancy is planned, prescribers usually advise stopping in advance rather than continuing until conception.
If pregnancy happens unexpectedly, contact the prescriber or GP promptly.
Breastfeeding
It is not known whether tirzepatide passes into human milk.
That means treatment or breastfeeding may need to be stopped, depending on clinical advice.
Contraception
Some prescribers discuss non-oral contraception or temporary extra barrier protection when starting or increasing Mounjaro.
This is because tirzepatide can affect absorption of oral contraceptives around initiation and dose escalation.
Fertility
Weight change can affect fertility, including in people with PCOS.
Contraception planning matters where pregnancy is not intended.
NHS access and private-provider pathways
NHS access
NICE recommends tirzepatide for obesity management alongside a reduced-calorie diet and increased physical activity in adults with a BMI of at least 35 and at least 1 weight-related comorbidity. NICE also says to use a lower BMI threshold, usually reduced by 2.5, for some ethnic backgrounds.
Higher threshold: NHS criteria are narrower than most private-provider screening.
Comorbidity required: weight-related medical conditions form part of the NICE recommendation.
Local access can vary: referral routes and commissioning can differ by area and service model.
Private-provider pathway
Private providers commonly assess BMI, medical history, current medication, contraindications, and whether treatment appears clinically appropriate. This route is how many UK adults currently explore access.
Complete a questionnaire or consultation
Provide height, weight, medical history, and medication details
Undergo provider review by an appropriate prescriber
If suitable, receive a prescription and fulfilment route
Continue with follow-up reviews where required
Costs vary by provider, dose, service model, and any extra consultation or delivery charges.
Ethnicity and BMI: NHS sources and NICE guidance use lower BMI thresholds for some ethnic backgrounds because health risks can appear at lower BMI levels than in the standard white-population thresholds. Useful next step: if the usual private-provider criteria may apply to you, compare provider information, displayed pricing, and service structure before proceeding. Compare provider information →
Common questions on eligibility
Can I be considered if my BMI is 28?
Possibly. This often depends on whether you have a relevant weight-related condition and whether the provider considers treatment clinically appropriate.
Do I need to try other approaches first?
NHS pathways often place more emphasis on structured previous attempts. Private providers vary, but most still review the wider context rather than treating medication as a stand-alone shortcut.
Can I be considered if I only want to lose a smaller amount of weight?
Providers usually look at BMI, clinical need, and broader health context rather than a target number alone.
Does PCOS help me meet the criteria?
PCOS can be one of the conditions that becomes relevant where BMI is lower, but assessment still depends on the provider’s overall clinical review.
What if I already take other medication?
You should disclose all current medication. Some medicines need extra caution or monitoring, and providers need the full picture before deciding whether prescribing is appropriate.
Can I switch from another GLP-1 treatment?
Some people do switch, but providers normally assess timing, previous treatment history, and the appropriate starting point rather than assuming a like-for-like continuation.
Key points to remember
BMI is one of the main screening criteria, but providers should assess broader clinical suitability too.
BMI 30 or above is often the standard private-provider threshold.
BMI 27 or above with a relevant condition may also be considered by some private providers.
Pregnancy and certain medical histories can make treatment unsuitable or require much closer review.
NHS access is narrower and follows NICE guidance rather than typical private-provider screening.
Private access is more common, but it still depends on prescriber review and provider terms.
Full disclosure of medical history matters.
Compare UK provider information
If the usual private-provider criteria may apply to you, review displayed pricing and provider information from UK providers below.
Loading price comparison…
Ready to review provider options?
Use the comparison table to review provider information, displayed pricing, and service structure from UK providers.
Review displayed pricing, fee structure, and wider cost considerations.
Read guide → Related guides: NHS access · Private prescriptions · BMI calculator Medical disclaimer: This page is informational and does not replace medical advice or a prescriber’s decision. Eligibility, prescribing, and follow-up always depend on individual clinical review and current provider criteria.
Helpful next steps
Useful checks before choosing a Mounjaro provider
Use these guides to understand access, safety, costs and provider details before deciding what to check directly with a UK provider.
Good comparison is not just a price list. These routes connect dose, eligibility, provider checks and ongoing support so you can make a clearer shortlist before leaving for a provider website.
What this adds: provider pages stay comparison-led, prices remain contextual, and users get obvious routes into dose, safety, eligibility and service-quality research.
